Company: REVB
Filing Date: 2025-05-29
Form Type: PRE 14A
Source: 0000950170-25-078948
Chunk: 72

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-05-29
Form: PRE 14A
Chunk 72
---
 the table have sole voting and investment power with respect to all shares of common stock owned by them.

| Name                                                    |     | Number of Shares   
 Beneficially Owned |        |     | Beneficial    
 Ownership (%) |      |
| Directors and Officers of Revelation(1):                |     |                    |        |     |               |      |
| James Rolke(2)                                          |     |                    | 30,142 |     |               | 3.1% |
| Jennifer Carver, BSN, MBA(3)                            |     |                    |    200 |     |               | *    |
| Jess Roper(4)                                           |     |                    |    196 |     |               | *    |
| Lakhmir Chawla, M.D. (5)                                |     |                    |    181 |     |               | *    |
| Chester S. Zygmont, III(6)                              |     |                    | 15,090 |     |               | 1.5% |
| All Directors and Officers as a Group (Six Individuals) |     |                    | 45,809 |     |               | 4.8% |

| * | Less than one percent. |

| (1) | Unless otherwise indicated, the business address of each of the individuals is c/o Revelation Biosciences, Inc., 4660 La Jolla Village Dr., Suite 100, San Diego, CA 92122. |

| (2) | Consists of (i) 42 shares of common stock held directly by Mr. Rolke, (ii) 30,095 shares of common stock from the February 11, 2025 Restricted Stock Award (“RSA”) grant to Mr. Rolke, (iii) 2 shares of common stock from Rollover RSU’s vesting and issuable within 60 days to Mr. Rolke, and (iv) 3 shares of common stock underlying Stock Options exercisable within 60 days by Mr. Rolke. |

| (3) | Consists of (i) 6 shares of common stock held directly by Ms. Carver (ii) 181 shares of common stock from the February 11, 2025 RSA grant to Ms. Carver, and (iii) 13 shares of common stock underlying Stock Options exercisable within 60 days by Ms. Carver.                                                                                                    |
| (4) | Consists of (i) 2 shares